Literature DB >> 8166985

Fibrinogen: an important risk factor for atherothrombotic diseases.

E Ernst1.   

Abstract

Epidemiological follow-up studies have suggested that fibrinogen is a major, primary cardiovascular risk factor. Cross-sectional results also show associations between fibrinogen and cardiovascular risk factors or diseases. Clinical cohort studies demonstrate that fibrinogen might also be a secondary risk factor. The determinants of the plasma level of fibrinogen in health and disease are known only incompletely. Our understanding of the mechanisms involved in the atherogenic actions of fibrinogen is similarly fragmentary. These might include blood coagulation, blood rheology, platelet aggregation, direct effects on the vascular wall, and the acute phase response. Thus, many questions are yet to be answered. Nevertheless, the data available at present strongly suggest that fibrinogen represents a major, independent cardiovascular risk factor. Fibrinogen should be considered for screening programmes aimed at identifying individuals at risk.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8166985     DOI: 10.3109/07853899409147322

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  3 in total

1.  Effect of allicin on Ca2+ responses of human lymphocytes.

Authors:  E I Astashkin; N A Belikova; N A Til'kunova; D Yu Zalepugin; M G Gleser; S V Grachev
Journal:  Dokl Biochem Biophys       Date:  2002 Sep-Oct       Impact factor: 0.788

2.  Antibacterial properties of Allium sativum L. against the most emerging multidrug-resistant bacteria and its synergy with antibiotics.

Authors:  Agnieszka Magryś; Alina Olender; Dorota Tchórzewska
Journal:  Arch Microbiol       Date:  2021-02-27       Impact factor: 2.552

3.  iTRAQ-Based Quantitative Proteomics Analysis of the Protective Effect of Yinchenwuling Powder on Hyperlipidemic Rats.

Authors:  Zheyu Zhang; Wenbo Wang; Ling Jin; Xin Cao; Gonghui Jian; Ning Wu; Xia Xu; Ye Yao; Dongsheng Wang
Journal:  Evid Based Complement Alternat Med       Date:  2017-08-14       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.